Bengaluru, November 17, 2026: The Indian Retinopathy of Prematurity Society (iROP) and Narayana Nethralaya, Rajajinagar, Bengaluru, marked World Prematurity Day by highlighting the need for timely eye screening in premature infants, following the approval of an artificial intelligence (AI) tool for retinopathy of prematurity (ROP) screening in India.
India records an estimated 30 lakh premature births annually, the highest in the world. ROP, a condition affecting the developing blood vessels in the retina of premature babies, can lead to blindness if not detected and treated early. The new AI tool aims to support screening teams by flagging retinal images for specialist review, potentially expanding access to early intervention.
AI tool receives CDSCO approval
The Central Drugs Standard Control Organisation (CDSCO) has approved the ROP AI tool, developed jointly by Remidio and KIDROP with funding from the Biotechnology Industry Research Assistance Council (BIRAC), Government of India. The software analyses bedside retinal images and helps identify cases needing specialist attention, even in areas with limited internet connectivity.
Babies weighing less than 2,000 grams at birth or born before 34 weeks of gestation are recommended to have their first ROP examination within the first month of life. Most require three to four screening sessions before being cleared of ROP risk, with some needing earlier or additional checks based on risk factors.
KIDROP expands screening and treatment
Narayana Nethralaya’s KIDROP program, operating since 2007 in partnership with the Government of Karnataka, provides ROP care in over 175 neonatal units across the state. According to Dr. Naren Shetty, Director of Narayana Nethralaya, KIDROP has screened 1,14,738 babies, conducted more than four lakh screening sessions, and delivered 6,493 treatments, all free of charge for babies born in government hospitals. The program also monitors children over time for vision outcomes and complications related to prematurity.
Dr. Anand Vinekar, Founder Program Director of KIDROP and Principal Investigator for the ROP AI project, said the KIDROP model has been extended beyond Karnataka to ten other Indian states with support from the Have A Heart Foundation and local clinical teams. By October 2026, over 28,000 babies had been screened and more than 2,000 treatments provided under these partnerships. KIDROP is also collaborating with teams in African nations, with AI expected to play a role in training and expediting specialist review.
iROP Society and AI development
Prof. Rajvardhan Azad, President of the Indian Retinopathy of Prematurity Society, noted that iROP has grown to a network of over 300 specialists nationwide. He emphasised the Society’s focus on raising awareness among parents, caregivers, and policymakers, and developing affordable screening methods for premature babies across India.
Dushyantsinh Anopsinh Jadeja, Senior Vice President – AI & Software at Remidio, said the AI tool was developed in collaboration with KIDROP and with support from the Department of Biotechnology, Government of India. The solution is designed to detect and grade ROP offline, enabling use in areas with limited connectivity.
About the organisations
The Indian Retinopathy of Prematurity Society (IROP), founded in July 2016, brings together specialists to prevent blindness in premature babies, promotes uniform screening and treatment guidelines, and supports research and outreach in underserved areas.
KIDROP (Karnataka Internet Assisted Diagnosis of Retinopathy of Prematurity) is the tele-ROP programme of Narayana Nethralaya, Bengaluru, and is among the world’s largest ROP screening networks. Remidio is a medical device company specialising in AI-driven eye care solutions, with CE-marked and FDA-registered devices used in over 55 countries.
Disclaimer: This article is based on a press release provided by the concerned organisation and has been edited for style and clarity with the assistance of AI tools. BusinessFortnight does not verify, endorse, or take responsibility for the claims, figures, or statements made in the original release.
